Biopharmaceutics Focus Group – Meeting report from “Physiologically Based Pharmacokinetic Modelling (PBBM) – Best Scientific Practices to Define Drug Product Performance: Latest Regulatory and Industry Perspectives”
Biopharmaceutics Focus Group - Meeting report from “Physiologically Based Pharmacokinetic Modelling (PBBM) - Best Scientific Practices to Define Drug Product Performance: Latest Regulatory and Industry Perspectives” 28 May 2026 Biopharmaceutics Focus Group The APS Biopharmaceutics Focus Group are pleased to share that the meeting report from the 2-day meeting on “Physiologically Based Pharmacokinetic Modelling (PBBM) - Best Scientific Practices to Define Drug Product Performance: Latest Regulatory and Industry Perspectives” and hosted by MHRA in London, UK is now available ((Physiologically Based Biopharmaceutics Modelling—Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report)). Around 80 scientists from industrial, academic, regulatory, and software companies came together to discuss the latest developments in PBBM and to debate key topics relevant to the establishment of [...]









